Ahead of an advisory committee meeting, the agency contradicted some of what the company had said about the benefits of its rare disease treatment.
The Food and Drug Administration said Monday that Capricor Therapeutics’ stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of Phase 3 trial — contrary to the company’s claims last year.
Capricor said in December that the... [547 chars]